Pass Regulatory Affairs Certification (RAC) Global Scope

exam in just 24 HOURS!

100% REAL EXAM QUESTIONS ANSWERS

Regulatory Affairs Certification (RAC) Global

Scope
Buy Complete Questions Answers File from

http://www.exams4sure.net/raps/rac-gs-examquestions-dumps.html
100% Exam Passing Guarantee & Money Back Assurance

Sample Questions
Question # 1:

A.

B.
C.

D.

Which of the following statements regarding the off-label use of drugs is

CORRECT?
Although the regulatory authority reviews and approves drugs for specific
indications, the approval does not limit the use of those drugs in clinical
practice.
The regulatory authority does not restrict physician prescribing for off-label
indications or regulate the manufacturer's promotion for such use.
Sponsors are allowed to distribute publications about unapproved uses of
approved drugs and devices as long as the marketing application is under
review by the regulatory authority.
The peer-reviewed literature can ensure high-quality off-label promotion of
medications, thereby increasing access to much needed drugs and devices.

Answer: A

Question # 2:
A drug product presents degradation during the manufacturing process. In
addition to the amount, what information should be provided FIRST in
order to use API overage?
A. Specification
B. Formulation
C. Property
D. Justification
Answer: D

Question # 3:
In the process of obtaining a product approval, a regulatory affairs
professional discovers that the product does not meet one of the specific
technical requirements of the regulation. However, competitors with
substantially similar products have claimed compliance with the

requirement and received approval. Which action should the regulatory

affairs professional take FIRST?
A. Discuss with the regulatory apriority and attempt to reach an acceptable
solution.
B. Inform the internal departments to redesign the product to comply with
this requirement.
C. Inform the regulatory authority that such a requirement is not
applicable to the product.
D. Notify senior management that the product cannot be registered.
Answer: A

Question # 4:
Which of the following statements regarding export regulations for an
approved product is CORRECT?
A. The product must not be in accord with the specifications of the foreign
purchaser.
B. The product must not be in conflict with the laws of the country to
which it is intended for export.
C. The product must not be labeled on the outside of the shipping package
that it is intended for export.
D. The product must not be sold or offered for sale in domestic commerce.
Answer: B

Question # 5:
The intermediate manufacturing process was changed during development
of a pharmaceutical. The change may impact the API specification. Which
functional area is responsible for the final approval of the change?
A. Production
B. Analytical
C. Quality
D. Regulatory
Answer: C, D

Question # 6:
Under which of the following circumstances would a regulatory authority
require a more detailed premarket submission, a more rigorous audit,
and/or the provision of more performance evaluation data than would
normally apply to an IVD device of that risk class?
A. The device is an updated version of a compliant device from the same
manufacturer and contains no substantive change.
B. Internationally recognized standards are available to cover the main
aspects of the device and have been used by the manufacturer.
C. The manufacturer's experience level with the type of IVD medical device
is limited.
D. The device incorporates well-established technology that is already
present in the market.
Answer: C

Question # 7:
According to WHO, what are the temperature and humidity conditions for a
Zone IVb long term stability study?
A.
B.
C.
D.

25: C and 60% RH

30 C and 35% RH
30c C and 65% RH
30: C and 75% RH

Answer: D

Question # 8:
During routine surveillance, a regulatory authority sent a company the
following communication: "Hepatotoxicity and suicidal behavior were
identified as potential safety issues for the company's product. The
regulatory authority is evaluating these issues to determine the need for

any regulatory action." Which action would be the most appropriate FIRST
step for the company to take?
A. Contact the regulatory authority to argue that its conclusions are wrong.
B. Contact the regulatory authority to discuss its findings.
C. Repeat the Hepatotoxicity tests and send the results to the regulatory
authority.
D. Wait for the regulatory authority's final publication on its findings.
Answer: B

Buy Complete Questions Answers File from

http://www.exams4sure.net/raps/rac-gs-exam-questionsdumps.html
100% Exam Passing Guarantee & Money Back Assurance
PDF Version + Test Engine Software Version
90 Days Free Updates Service
Valid For All Countries

http://www.exams4sure.net/raps/rac-gs-examquestions-dumps.html